Immunotherapy in bronchial asthma

Current Opinion in Pulmonary Medicine

Volumn 6, Issue 1, 2000, Pages 50-54

  Alvarez Cuesta, E ^a   Gonzelez Mancebo E ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; IMMUNOGLOBULIN E;

ALLERGIC RHINITIS; ASTHMA; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DUST; HUMAN; IMMUNOTHERAPY; MITE; REMISSION; RESPIRATORY TRACT ALLERGY; REVIEW; RISK FACTOR;

EID: 0033835259     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200001000-00010     Document Type: Review

References (40)

1. Allergen immunotherapy: Therapeutic vaccines for allergic diseases. WHO Position Paper
2. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials
3. House dust mite control measures in the management of asthma: Meta-analysis
4. Monoclonal antibody-standardized cat extract immunotherapy: Risk-benefit effects from a double-blind placebo study
5. Allergen specific immunotherapy for asthma
6. Specific immunotherapy for asthma in paediatrics; Meta-analysis
7. Immunotherapy: Position paper of the European Academy of Allergy and Clinical Immunology
8. Immunotherapy with a standardized Dermatophagoides pteronissimus extract: V. Duration of efficacy of immunotherapy after its cessation
9. Immunotherapy with a standardized Dermatophagoides pteronissimus extract: VI. Specific immunotherapy prevents the onset of new sensitizations in children
10. Preventive allergy treatment (PAT). Symposium on specific allergy 1996
11. Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis
12. Effect of specific immunotherapy with house dust mite extract on the bronchial responsiveness of paediatric asthma patients
13. Immunotherapy in children with allergic asthma: Effect on bronchial hyperreactivity and pharmacotherapy
14. Position paper: Local Immunotherapy
15. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: A double-blind, placebo-controlled study
16. Sublingual immunotherapy using a birch pollen extract: Short-term, double-blind, placebo-controlled study
17. Randomized controlled study of local immunotherapy with an allergoid in mite-induced rhinoconjunctivitis
18. Sublingual immunotherapy with a standardized grass pollen extract: A double-blind placebo-controlled study
19. Efficacy and safety of oral immunotherapy in respiratory allergy to Parietaria judaica pollen: A double-blind study
20. Non-especific hyperreactivity before and after nasal specific immunotherapy
21. Effect of hyposensitization upon the immediate and late asthmatic reaction and upon histamine reactivity in patients allergic to house dust mite (Dermatophagoides pteronyssinus)
22. Oral immunotherapy with grass pollen in enterosoluble capsules
23. Sublingual versus injective immunotherapy in grass pollen allergic patients: A double blind (double dummy) study
24. Injective versus sublingual immunotherapy in Alternaria tenuis allergic patients
25. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma: A placebo controlled study
26. Long-term clinical efficacy of grass-pollen immunotherapy
27. Immunotherapy with partially purified and standardized tree pollen extracts: IV. Results from long-term (6 years) follow-up
28. Long-term follow-up of patients treated with a three year course of cat or dog immunotherapy
29. Long term effect of specific immunotherapy (SIT) in tree pollen allergy
30. A comparative study of the clinical efficacy of immunotherapy and conventional pharmacological treatment for patients with perennial allergic rhinitis
31. Immunotherapy with a standardized Dermatophagoides pteronissynus extract: V. Duration of the efficacy of immunotherapy after its cessation
32. Significant reduction of nonspecific bronchial reactivity in patients with Dermatophagoides pteronyssinus-sensitive allergic asthma under therapy with allergen-antibody complexes
33. Persistence of efficacy after a brief course of polymerized ragweed allergen: A controlled study
34. Booster immunotherapy
35. A prospective safety-monitoring study of immunotherapy with biological standardized extracts
36. Risk factors for adverse systemic reactions occurring during immunotherapy with standardized Dermatophagoides farinae extracts
37. El costo del tratamiento por asma en Espana en las enfermedades alergicas respiratorias en atencion primaria: Diagnostico y tratamiento Etiologico
38. Allergen immunotherapy: A long-term perspective
39. Utilization and cost of immunotherapy for allergic asthma and rhinitis